Abstract. This study aims to evaluate the quality of Chinese listed pharmaceutical companies about their environmental information disclosure (EID) and to find EID influencing factors of Chinese pharmaceutical industry. We collected 121 Chinese listed pharmaceutical companies' EID from annual reports and corporate social responsibility (CSR) reports in 2015-2017 to establish the Environmental Performance Assessment Indicator System and determine the inflencing factors. In our study, we found that Chinese pharmaceutical listed companies' EID still lacks a unified framework and complete information. The type of listed exchanges, the size of companies, the ownership of companies and years all effect the EID quality of Chinese pharmaceutical listed companies. In order to improve the overall quality of corporate EID, we suggest that the government unify the domestic CSR guidelines immediately and introduce regulations to require companies to disclose more quantitative environmental information.
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